Evidence map›Paper›PMID 28079542›Full record

ArticleAnnals of surgery2018

Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium.

Marc A Attiyeh, Carlos Fernández-Del Castillo, Mohammad Al Efishat, Anne A Eaton, Mithat Gönen, Ruqayyah Batts, Ilaria Pergolini, Neda Rezaee, Keith D Lillemoe, Cristina R Ferrone and 10 more

Abstract readMulticenter StudyValidation Study
In one paragraph

Article in Annals of surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Marc A AttiyehDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Carlos Fernández-Del CastilloDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Mohammad Al EfishatDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Anne A EatonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Mithat GönenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Ruqayyah BattsDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Ilaria PergoliniDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Neda RezaeeDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Keith D LillemoeDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Cristina R FerroneDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Mari Mino-KenudsonDepartment of Pathology, Massachusetts General Hospital, Boston, MA.
Matthew J WeissDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.
John L CameronDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Ralph H HrubanDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Michael I D'AngelicaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Ronald P DeMatteoDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
T Peter KinghamDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
William R JarnaginDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Christopher L WolfgangDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Peter J AllenDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreasR01CA182076 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Peter J Allen · 2014 to 2026
$3.6M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA182076
6 · The paper itself

Abstract

objectivePrevious nomogram models for patients undergoing resection of intraductal papillary mucinous neoplasms (IPMNs) have been relatively small single-institutional series. Our objective was to improve upon these studies by developing and independently validating a new model using a large multiinstitutional dataset. SUMMARY BACKGROUND DATA: IPMNs represent the most common radiographically identifiable precursor lesions of pancreatic cancer. They are a heterogenous group of neoplasms in which more accurate markers of high-grade dysplasia or early invasive carcinoma could help avoid unnecessary surgery in 1 case and support potentially curative intervention (resection) in another.

methodsProspectively maintained databases from 3 institutions were queried for patients who had undergone resection of IPMNs between 2005 and 2015. Patients were separated into main duct [main and mixed-type (MD)] and branch duct (BD) types based on preoperative imaging. Logistic regression modeling was used on a training subset to develop 2 independent nomograms (MD and BD) to predict low-risk (low- or intermediate-grade dysplasia) or high-risk (high-grade dysplasia or invasive carcinoma) disease. Model performance was then evaluated using an independent validation set.

resultsWe identified 1028 patients who underwent resection for IPMNs [MD: n = 454 (44%), BD: n = 574 (56%)] during the 10-year study period. High-risk disease was present in 487 patients (47%). Patients with high-risk disease comprised 71% and 29% of MD and BD groups, respectively (P <0.0001). MD and BD nomograms were developed on the training set [70% of total (n = 720); MD: n = 318, BD: n = 402] and validated on the test set [30% (n = 308); MD: n = 136, BD: n = 172]. The presence of jaundice was almost exclusively associated with high-risk disease (57 of 58 patients, 98%). Cyst size >3.0 cm, solid component/mural nodule, pain symptoms, and weight loss were significantly associated with high-risk disease. C-indices were 0.82 and 0.81 on training and independent validation sets, respectively; Brier scores were 0.173 and 0.175, respectively.

conclusionsFor patients with suspected IPMNs, we present an independently validated model for the prediction of high-risk disease.

Indexed as

Neoplasm StagingNomogramsPancreatectomyAdenocarcinoma, MucinousAdolescentAdultAgedAged, 80 and overCarcinoma, Pancreatic DuctalCarcinoma, PapillaryFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Invasivenesscancerdysplasiaintraductal papillary mucinous neoplasmIPMNnomogrampancreasthe pancreatic surgery consortium

Identifiers

PMID28079542
PMCPMC5565720

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.